Substance / Medication

Reserpine

Overview

Active Ingredient
reserpine
RxNorm CUI
9260

Indications

box warning Hypertension (see).

Labeler: Pfizer LabsUpdated: 2006-02-06T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

This fixed combination drug is not indicated for initial therapy of hypertension. Hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. The treatment of hypertension is not

Contraindications

When this intervention should not be used

A. Related to polythiazide B. Related to reserpine Advanced renal or hepatic failure. Hypersensitivity to this or other sulfonamide derivatives. Demonstrated hypersensitivity. Patients with a history of mental depression. Demonstrated peptic ulcer or ulcerative colitis.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Intensive Blood Pressure Control in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular and Microvascular Outcomes.
Mousavi Asma, Shojaei Shayan, Abhari Amir Parsa et al. · Am J Hypertens · 2026
PMID: 40717314Meta-Analysis
The Effect of SGLT2 Inhibitors on Blood Pressure in Relation to Baseline Kidney Function: A Systematic Literature Review and Data Analysis.
Møller Charlotte Agergaard, Nielsen Steffen Flindt, Mose Frank Holden · Am J Hypertens · 2026
PMID: 40717316Meta-Analysis
Arterial spin labeling MRI in assessing cerebral blood flow changes due to hypertension: a systematic review.
Muthu Sathya Sabina, Sukumar Suresh, Kadavigere Rajagopal et al. · J Hypertens · 2026
PMID: 41002015Meta-AnalysisFull text (PMC)
The effects of reserpine on depression: A systematic review.
Strawbridge Rebecca, Javed Rahila R, Cave Jeremy et al. · J Psychopharmacol · 2023
PMID: 36000248Meta-AnalysisFull text (PMC)
Chlorpromazine versus reserpine for schizophrenia.
Nur Selin, Adams Clive E · Cochrane Database Syst Rev · 2016
PMID: 27124109Meta-AnalysisFull text (PMC)
Blood pressure-lowering efficacy of reserpine for primary hypertension.
Shamon Sandy D, Perez Marco I · Cochrane Database Syst Rev · 2016
PMID: 27997978Meta-AnalysisFull text (PMC)
Chlorpromazine vs Reserpine for Schizophrenia.
Nur Selin, Adams Clive E · Schizophr Bull · 2016
PMID: 27098890Meta-AnalysisFull text (PMC)
Blood pressure lowering efficacy of reserpine for primary hypertension.
Shamon Sandy D, Perez Marco I · Cochrane Database Syst Rev · 2009
PMID: 19821434Meta-Analysis
A double-blind, placebo-controlled trial of reserpine for the treatment of cocaine dependence.
Winhusen Theresa, Somoza Eugene, Sarid-Segal Ofra et al. · Drug Alcohol Depend · 2007
PMID: 17628352RCTFull text (PMC)
A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence.
Berger S Paul, Winhusen Theresa M, Somoza Eugene C et al. · Addiction · 2005
PMID: 15730350Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Reserpine (substance)
SNOMED CT
387447004
UMLS CUI
C0035179
RxNorm CUI
9260
Labeler
Pfizer Labs

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.